Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON

Ryan J. Hartmaier, Aleksandra A. Markovets, Myung Ju Ahn, Lecia V. Sequist, Ji Youn Han, Byoung Chul Cho, Helena A. Yu, Sang We Kim, James Chih Hsin Yang, Jong Seok Lee, Wu Chou Su, Dariusz M. Kowalski, Sergey Orlov, Song Ren, Paul Frewer, Xiaoling Ou, Darren A.E. Cross, Nisha Kurian, Mireille Cantarini, Pasi A. Jänne

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON'. Together they form a unique fingerprint.

Nursing and Health Professions

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology